Exelixis, Inc. (NASDAQ:EXEL) has lost 55% of its share prices after the release of COMET-1, phase 3 pivotal trials, which were unable to meet the primary endpoint of indicating higher survival rate in patients suffering from prostate cancer. According to the CEO of Exelixis, Inc. (NASDAQ:EXEL), Michael M. Morrissey, “We are very disappointed that COMET-1…